Volume 155, Issue 4, Pages 974-976 (October 2018) ROCKin’ Intestinal Cell Fate: A Potential Avenue to Improve Glucose Sensitivity  Joep Beumer  Gastroenterology  Volume 155, Issue 4, Pages 974-976 (October 2018) DOI: 10.1053/j.gastro.2018.09.005 Copyright © 2018 AGA Institute Terms and Conditions

Figure 1 Different strategies to target enteroendocrine cells (EECs) for therapeutic interventions EECs can be targeted for clinical benefits through different approaches. First, secretion or stability of the product can be manipulated to expand the hormone output from a same number of EECs. Dipeptidyl peptidase-4 inhibitors are an example that prevent inactivation of Glp1, therefore increasing serum levels of the active form of the peptide. Many molecules that induce secretion of EEC hormones (secretagogues) such as glucose have been described, but no current treatments are based on this principle. An alternative approach currently not used in the clinic is to target the development of EECs to decrease or increase the number of specific EEC subtypes, depending on the therapeutic need. Petersen et al show a well-tolerated novel intervention, inhibition of ROCK signaling, as a promising strategy to increase the number of Glp1-producing L-cells (right). Gastroenterology 2018 155, 974-976DOI: (10.1053/j.gastro.2018.09.005) Copyright © 2018 AGA Institute Terms and Conditions